Evolving Our Understanding and Management of Geographic Atrophy, Part 2 - Live Q&A
Media formats available:
Details
Presenters
Overview
This webinar with live Q&A will focus on the management of patients with geographic atrophy (GA). Join these well-known retina experts as they discuss the prevalence of GA, the risk factors for disease, ideal imaging modalities to diagnose and monitor its progression; and the growing pipeline of GA treatments and their mechanisms of action. The webinar will also feature case study discussions.Supported by an educational grant from Apellis. Learning Objectives
Upon completion of this activity, the participant should be able to: - Describe the prevalence of age-related macular degeneration and classify by severity: early, intermediate, and advanced (ie, wet AMD and geographic atrophy [GA]).
- Explain the pathogenesis of GA.
- Distinguish which imaging modalities are best suited for GA evaluation.
- Categorize new therapies in the pipeline for GA.
- Evaluate the functional and anatomic outcomes used in managing patients with GA.
Accreditation
Provided by Evolve Medical Education 
Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers: Internet Explorer 11 for Windows Edge (recent versions; Chromium-based) for Windows Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements: 4GB+ RAM
Recommended internet speed 5Mbps+
Faculty and Disclosures
DISCLOSURE POLICY
Faculty:
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Roger A. Goldberg, MD, MBAProgram ChairPartner, Bay Area Retina Associates
Faculty, CPMC Ophthalmology Residency
San Francisco Bay Area, California
Caroline R. Baumal, MD Professor of Ophthalmology New England Eye Center Tufts Medical Center Tufts University Boston, Massachusetts
Aleksandra V. Rachitskaya, MD
Cole Eye Institute
Assistant Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio
SriniVas Sadda, MD
President and Chief Scientific Officer
Doheny Eye Institute
Professor of Ophthalmology
University of California – Los Angeles
Geffen School of Medicine
Los Angeles, California
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:Roger A. Goldberg, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Aerie, Allergan, Apellis, Carl Zeiss Meditec, Chengdu, Genentech, Graybug Vision, Neurotech, Novartis, Ribomics, and Santen. Speaker’s Bureau: Allergan, and Genentech.
Caroline Baumal, MD, and or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Apellis, Alcon, Carl Zeiss Meditec, Genentech, and Novartis.
Aleksandra Rachitskaya, MD, and or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Carl Zeiss Meditec, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Genentech, and Novartis.
Srinivas R. Sadda, MD, and or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Amgen, Genentech/Roche, Grant/Research Support: Allergan, Carl Zeiss Meditec, CenterVue, Heidelberg Engineering, NGM Bio, Nidek, Novartis, Optos, Oxurion, Regeneron, Topcon, and 4DMT. Speaker’s Bureau: Merck, Nidec, and Topcon. Other Financial Support: Carl Zeiss Meditec, CenterVue, Heidelberg Engineering, Nidek, Optos, and Topcon.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Apellis. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!